Avantium provides Crystal 16TM to all research sites of Sanofi-Aventis

Avantium Technologies has announced an agreement with Sanofi-Aventis for the deployment of its proprietary Crystal16™ at all R&D centres of Sanofi-Aventis.

Sanofi-Aventis has selected the Crystal16™:
- for the enhancement of its crystallisation research capabilities
- to increase the experimental throughput of its scientists
- to perform crystallisation experiments on a smaller scale

The Crystal16™ is a novel and proprietary platform that can be used for a range of applications in pharmaceutical and chemical research.

Users of the Crystal16™ are capable of running 16 experiments in parallel retrieving maximum knowledge about the crystallisation process and solid-state of their product.

Avantium International B.V.

Avantium International B.V.
R&D services


DownloadFull Press Release